New ultrasound method could replace painful kidney biopsies for transplant patients
NCT ID NCT02201537
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether special ultrasound scans can detect kidney damage in people who have received a kidney transplant. 141 transplant recipients had ultrasound imaging at 15 days, 3 months, and 12 months after surgery. The goal was to see if these scans could measure kidney stiffness and blood flow as accurately as a biopsy to diagnose chronic kidney disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
141 people
The number who actually took part.
- Started
-
Mar 2013
- Finished
-
Mar 2016
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years; * Patient with informed consent; * Recipient of a living donor graft or cadaveric donor patient; * No contraindication for biopsy of the graft; * No contraindication to the injection of SonoVue ®: * hypersensitivity to sulfur hexafluoride * acute coronary syndrome, unstable ischemic heart disease (myocardial infarction phase formation or evolution, typical resting angina in the previous 7 days, significant worsening of cardiac symptoms in the previous 7 days, recent intervention on the coronary arteries or another factor suggesting clinical instability (eg, recent deterioration of ECG changes in clinical or laboratory parameters), acute heart failure, stage III or IV heart failure, severe arrhythmias. * right-left shunt, severe pulmonary hypertension (PAP\> 90 mmHg), uncontrolled systemic hypertension, respiratory distress syndrome * Affiliated to a social security scheme Exclusion Criteria: * Refusal to participate in the study; * Inability / refusal to give informed consent; * contraindication for biopsy testing graft; * Presence of a contraindication to the injection of SonoVue ®. * Presence of a peripheral venous access in a non-restricted already infused patient, not pickable under ultrasound * Breastfeeding, pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic kidney disease in kidney transplant recipients are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NECKER Hospital
Paris, 75015, France